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Purpose: The present study assessed the influence of L-DOPA administration on
neostriatal dopamine (DA) transporter (DAT) binding in relation to motor and exploratory
behaviors in the rat.
Methods: Rats received injections of 5 mg/kg L-DOPA, 10 mg/kg L-DOPA or vehicle. Motor
and exploratory behaviors were assessed for 30 min in an open field prior to administration
of [123I]FP-CIT. Dopamine transporter binding was measured with small animal single-
photon emission computed tomography (SPECT) 2 h after radioligand administration for
60 min.
Results: Both L-DOPA doses significantly reduced DAT binding and led to significantly less
head-shoulder motility and more sitting relative to vehicle. Moreover, 10 mg/kg L-DOPA
induced less distance traveled and ambulation than 5 mg/kg L-DOPA. Analysis of time-
behavior (t-b) curves showed that L-DOPA-treated animals relative to vehicle exhibited (1)
a faster rate of increase in duration of sitting; (2) a slower rate of increase in duration of
head-shoulder motility; and (3) a slower rate of decrease in frequency of head-shoulder
motility.
Conclusions: The reductions of striatal DAT binding after L-DOPA challenges reflected
elevated concentrations of synaptic DA. L-DOPA-treated animals showed less head-
shoulder motility and more sitting than vehicle-treated animals, indicating an association
between less behavioral activity and increased availability of striatal DA. The faster increase
of sitting duration to a higher final level and the slower increase of head-shoulder motility to
a lower final level relative to controls may be interpreted in terms on behavioral habituation
to a novel environment.
Keywords: dopamine transporter, L-DOPA methylester, motor behavior, exploratory behavior, habituation,
time-behavior curves, small animal SPECT
INTRODUCTION
Presynaptic monoamine transporters such as the dopamine trans-
porter (DAT) regulate neurotransmitter concentrations available
for receptor binding at the postsynaptic site. Deficiencies of
DAT function play a major role in the pathophysiology of psy-
chiatric disorders (for review see, e.g., Nikolaus et al., 2009b,
2010, 2012, 2014) and a variety of neurological conditions (for
review see, e.g., Nikolaus et al., 2009a) including idiopathic and
early-onset Parkinson’s disease (PD) and the “Parkinson Plus”
syndromes multiple system atrophy and progressive supranu-
clear palsy. In idiopathic PD and “Parkinson Plus” syndromes,
DAT function is affected to different degrees, while it is unim-
paired in essential tremor (e.g., Plotkin et al., 2005). There-
fore, DAT imaging with positron emission tomography (PET)
or single-photon emission computed tomography (SPECT) has
become an important tool to differentiate between movement
disorders.
The treatment of choice for idiopathic PD is L-3,4-
dihydroxyphenylalanine (L-DOPA), which passes the blood-brain
barrier via a saturable transporter and is converted to dopamine
(DA) in the presynaptic terminal by aromatic L-amino acid decar-
boxylase (for review see Okereke, 2002). Initially, the increased
availability of DA compensates for the decline of DA synthesis, DA
storage and DAT binding, which are characteristic for idiopathic
PD. With extended L-DOPA treatment, however, inhibitory feed-
back mechanisms at the presynaptic terminal lead to a reduction
of endogenous DA formation, resulting in an aggravation of
DAergic depletion. Common features of long-term treatment
with L-DOPA, therefore, are dyskinesias, on-off phenomenon and
wearing-off phenomenon (for review see Cenci et al., 2011).
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As of yet, the displaceability of DAT radioligands by endoge-
nous DA in in vivo imaging is still a matter of debate. The process
of nigrostriatal neurodegeneration leads to a progressive reduc-
tion of DAT binding sites and diminishes the capacity to synthe-
size and release DA contingent on administration of the precursor
molecule. Thus, it is likely that the extent of neurodegeneration
determines whether a reduction of radioligand binding occurs
after treatment with L-DOPA. If DAT binding is assessed in less
severe cases in baseline and after L-DOPA challenge, it may be
assumed that DA is released into the synaptic cleft in relation
to the extent of striatal lesion leading to competition with the
exogenous radioligand and a reduction of DAT binding compared
to baseline. Accordingly, acute and chronic treatment with clinical
and higher L-DOPA doses has been shown to significantly reduce
radioligand binding to the DAT in PD patients with lower disease
severity (Guttman et al., 2001), in healthy rats (Dresel et al.,
1998; Nikolaus et al., 2011b, 2013) and in the intact striata of
unilaterally 6-hydroxydopamine-lesioned animals (Sossi et al.,
2010).
In rats, L-DOPA is known to affect motor behaviors, leading to
decreased activity in mature animals after doses of 12.5–50 mg/kg
(McDevitt and Setler, 1981) and to increased activity in immature
animals after 150 mg/kg (Grigoriadis et al., 1996). In a previous
study (Nikolaus et al., 2013), we presented preliminary in vivo
evidence for an association between neostriatal DAT binding and
parameters of motor and exploratory behavior after treatment
with L-DOPA doses of 5 and 10 mg/kg. In the present study,
we expand on these findings with a modified design that allows
comparisons between groups rather than between treatment and
baseline and a more differentiated approach to the assessment
of behaviors. Generally, drug effects on behavior are assessed
by evaluating the relationship between dose and magnitude of
behavioral response. Since, however, compounds acting on the
DAergic system are also likely to influence behavior over time,
our rationale was to gain information on the temporal dynamics
of behavioral alterations. For this purpose, we plotted the indi-
vidual behaviors against the time post-injection and determined
time-behavior (t-b) curves by deriving suitable mathematical
models for the vehicle-treated animals. These models were fit to
the behavioral data of the animals treated with 5 or 10 mg/kg
L-DOPA, and the resulting t-b curves were compared between
treatment groups.
Furthermore, we aimed to investigate, whether alterations of
behaviors can be related to changes in magnitude of DAT binding
relative to controls. Therefore, motor and exploratory behaviors
were correlated with DAT binding and subjected to a multivariate
principal component analysis (PCA) and a cluster analysis (CA).
MATERIALS AND METHODS
ANIMALS
The present study employed a total of 52 adult male Wistar rats
(TVA, Heinrich-Heine University, Düsseldorf, Germany), weigh-
ing 395 ± 49 g (mean ± SD). Data obtained on 19 animals
out of this pool were reported as a pilot study (Nikolaus et al.,
2013). Dopamine transporter binding and behavior were jointly
assessed after treatment with 5 mg/kg L-DOPA (n = 15), 10 mg/kg
L-DOPA (n = 14) and vehicle (0.9% saline; n = 16). Seven
animals merely underwent behavioral assessment (5 mg/kg L-
DOPA, n = 3; 10 mg/kg L-DOPA, n = 3; saline, n = 1). Rats were
maintained in standard macrolon cages (590 × 380 × 200 mm;
3 animals per cage) in a climate cabinet (Scantainer, Scanbur BK,
Karslunde, Denmark; temperature, 20◦C; air humidity, 70%) with
an artificial ligh-dark cycle (lights on ar 6:00 a.m.; lights off at
6:00 p.m.) and food and water freely available. The study was
approved by the regional authority and carried out in accordance
with the “Principles of laboratory animal care” (NIH publication
No. 86–23, revised 1985) and the German Law on the Protection
of Animals.
SPECT CAMERA
The small animal tomograph (“TierSPECT”) was described in
detail elsewhere (Schramm et al., 2000). Tomographic resolutions
(FWHM) are to 3.4 and 2.8 mm for 123I and 99mTc, respec-
tively, while sensitivities amount to 16 (123I) and 22 cps/MBq
(99mTc). A low-energy ultra-high-resolution parallel-hole colli-
mator (LEUHR, 37 × 1 × 0.2 mm3) was mounted in front of the
detector head. Data were acquired in a 128 × 128 matrix with a
pixel width and a slice thickness of≈ 0.664 mm, respectively. Data
were acquired for 60 min in a step-and-shoot mode over a circular
orbit in angular steps of 6◦ (60 projections, 60 s/projection) using
a 65 mm radius of rotation. Reconstruction was performed with
an iterative ordered-subset-expectation-maximization algorithm
(3 iterations, 4 subsets/iteration). No post-filtering procedure
was applied. An attenuation correction of 0.11 cm−1 was imple-
mented for both 123I and 99mTc assuming a uniformly attenuating
medium.
DAT IMAGING STUDIES
Dopamine transporter binding was assessed after challenge
with L-DOPA methylester (Sigma-Aldrich, Taufkirchen, Ger-
many; dose, 5 or 10 mg/kg; concentrations, 5 or 10 mg/ml)
plus benserazide (Sigma-Aldrich, Taufkirchen, Germany; dose,
10 mg/kg; concentration, 10 mg/ml) or vehicle (0.9% saline;
B. Braun Melsungen AG, Melsungen, dose: 1 ml/kg). Benser-
azide is peripherally-acting aromatic L-amino acid decarboxylase
inhibitor, which is applied in order to prevent the metabolization
of L-DOPA before it passes the blood-brain barrier (Shen et al.,
2003).
Challenges were applied intraperitoneally (i.p.) 30 min
prior to radioligand application, since maximum striatal DA
concentrations are reached at 30 min after i.p. L-DOPA and
remain stable for approximately 2 h (Shen et al., 2003).
L-3,4-dihydroxyphenylalanine and benserazide were admin-
isted simultaneously, since previous investigations had shown
that pre-treatment with benserazide up to 3 h prior to
L-DOPA administration did not alter motor responses to L-
DOPA compared to simultaneous application of both com-
pounds (Tayarani-Binazir et al., 2010). Thirty minutes after
L-DOPA plus benserazide or saline, animals received i.p. injec-
tions of 0.9 ml/kg ketaminehydrochloride (Ketavet®, Pharma-
cia GmbH, Erlangen, Germany; concentration, 100 mg/ml) and
0.4 ml/kg xylazinehydrochloride (Rompun® Bayer, Leverkusen,
Germany; concentration, 2%). Then 27 ± 4 MBq [123I]-FP-CIT
(DATSCAN, GE Healthcare, München, Germany; concentration
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range, 0.07–0.13 µg/ml, specific activity range, 2.5–4.5 × 1014
Bq/mmol at reference time) were applied into the lateral tail vein
using a winged infusion needle set. The tube was rinsed with 1 ml
0.9% saline amounting to a total injection volume of 1.3 ml.
Since the equilibrium of [123I]FP-CIT binding is reached
at 2 h post-injection with the ratio of specific to non-specific
striatal uptake remaining stable over the following 4 h (Booi
et al., 1997), SPECT measurements were started 2 h after
radioligand application. Since SPECT measurements were con-
ducted over 1 h, animals were kept under anesthesia for a total
of 3 h.
BEHAVIORAL STUDIES
Immediately after the injection of 5 mg/kg L-DOPA, 10 mg/kg
L-DOPA or vehicle rats were placed into the center of a
cage with a topunit equipped with light-emitting diodes and
a charge-coupled device (CCD) camera (Phenotyper®, Noldus
Information Technology, Wageningen, Netherlands; open field
dimensions, 45 cm × 45 cm × 56 cm). Durations (s) and
frequencies (n) of motor and exploratory behaviors were rated
blindly in blocks of 5 min for a total of 30 min using EthoVision
XT (Noldus Information Technology, Wageningen, Netherlands).
Rated behaviors were: (A) ambulation as a measure of motor
activity; (B) sitting without any motion; (C) rearing (freely stand-
ing or leaning against the wall) as a measure of both motor activity
and non-selective attention according to Aspide et al. (1998);
(D) head-shoulder motility (movements of head and shoulders
while the animal was sitting), a parameter recently introduced as
a further measure of motor activity and non-selective attention
(Nikolaus et al., 2013); (E) grooming (fur, paw and claw licking,
scratching). In addition, based on the dislocation of the animal’s
center point EthoVision XT automatically determined the dis-
tance in centimeters traveled by the rat. Following the behavioral
trials, animals were anesthetized and administered [123I]FP-CIT
as described above.
EVALUATION OF DAT IMAGING STUDIES
Imaging data were evaluated using the Multi-Purpose-Imaging-
Tool (MPI-Tool V3.29, Advanced Tomo Vision GmbH, Kerpen,
Germany) as previously described (e.g., Nikolaus et al., 2007,
2011a, 2013). Briefly, maximum striatal count rates (counts/pixel)
were determined on coronal slices by defining a circular region
covering an area of 1.5 mm2, which comprised a total of 11 pixels.
On the same slices, cerebellar reference count rates (counts/pixel)
were obtained in an elliptic region (area, 7 mm2 comprising
53 pixels) approximately 15 mm posterior to the frontal cortex
corresponding anatomically to the rat cerebellum. Left and right
striatal counts rates were averaged. The equilibrium ratios of the
distribution volumes of the specifically and the non-specifically
bound compartment (V3” = VT(striatum)/VT(cerebellum)–1)




Distributions of binding data were assessed with the non-
parametric Kolmogorov-Smirnov test (α = 0.05). In each
pre-treatment condition, V3” values as well as cerebellar count
rates were found to be normally distributed (0.313 ≤ p ≤ 0.989).
Striatal V3” values and cerebellar radioactivity count rates
obtained after 5 mg/kg L-DOPA, 10 mg/kg L-DOPA or vehi-
cle were compared with the parametric independetnt t test
(two-sided, α = 0.0167 after Bonferroni correction for multi-
ple comparisons). Calculations were performed using IBM SPSS
Statistics 22.
Behavioral studies
Distributions of behavioral data (traveled distance [cm], dura-
tion [s] and frequency [n] of ambulation, sitting, rearing, head-
shoulder motility and grooming in 5-min bins were assessed
with the non-parametric Kolmogorov-Smirnov test (α = 0.05).
Since in all pre-treatment conditions, the majority of behav-
ioral parameters was not found to be normally distributed
(0.2 ≤ p ≤ 0.0001), behaviors in each 5-min time bin were com-
pared between groups using the non-parametric Mann-Whitney
U test (two-sided, α = 0.0167 after Bonferroni correction for
multiple comparisons). Calculations were performed using IBM
SPSS Statistics 22.
The medians of the individual behavioral parameters obtained
after vehicle (Y-axis: traveled distance, duration and frequency of
ambulation, sitting, rearing, head-shoulder motility or groom-
ing) were plotted against the end-points of the individual time
frames (X-axis). Upon visual inspection of the data, the fol-
lowing mathematical models were fit to the individual behav-
ioral parameters, using either non-linear or linear regression
analysis with the regression coefficient (R2) as a measure for
the goodness of fit: (1) traveled distance, exponential function
(y(t) = a ∗ exp (−K ∗ x) + plateau with a, value at the
time t; K, rate constant; t, time); R2 = 0.906; (2) ambula-
tion duration; exponential function; R2 = 0.889; (3) ambula-
tion frequency; exponential function; R2 = 0.946; (4) sitting
duration; linear function (y = ax + b with a, slope and b, y-
intercept); R2 = 0.778; (5) sitting frequency; quadratic function
(y = a + bx + cx2 with a, absolute term; bx, linear term; cx2,
quadratic term); R2 = 0.636; (6) rearing duration; exponential
function; R2 = 0.858; (7) rearing frequency; exponential function;
R2 = 0.957; (8) duration of head-shoulder motility; quadratic
function; R2 = 0.968; (9) frequency of head-shoulder motility;
linear function; R2 = 0.925).
The same models were fit to the behavioral data obtained
after 5 and 10 mg/kg L-DOPA with R2 values respectively of
0.997 and 0.991 (traveled distance), 0.985 and 0.975 (ambula-
tion duration), 0.991 (ambulation frequency), 0.945 and 0.782
(sitting duration), 0.786 and 0.532 (sitting frequency), 0.968 and
0.988 (rearing duration), 0.992 and 0.976 (rearing frequency),
0.879 and 0.477 (duration of head-shoulder motility) and 0.695
and 0.84 (frequency of head-shoulder motility). Due to the low
expression of both grooming duration and grooming frequency,
the grooming data could not be reasonably fit to any mathe-
matical model. Curve fittings were performed using GraphPad
Prism (version 3.0 for Windows, GraphPad Software, San Diego,
USA). T-b curves were compared between treatment groups using
the F test (α = 0.0167 after Bonferroni correction for multiple
comparisons).
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FIGURE 1 | (A) Coronal [123I]FP-CIT images of rat heads after pre-treatment
with vehicle (0.9% saline), 5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The
reduction in striatal DAT binding after both L-DOPA doses is clearly visible.
All images show V3” values; it is understood, that the calculation of V3” is
only valid for regions of specific radioligand binding such as the rat
striatum. Calculations were performed using MATLAB (version 4.2c or
version 6, The MathWorks Inc., Novi, USA). (B) Striatal equilibrium ratios
(V3”) after vehicle, 5 mg/kg L-DOPA and after 10 mg/kg L-DOPA. Rendered
are means and standard deviations of the means. The circles represent the
individual animals. For significant between-group differences the respective
p values are given (two-tailed independent t test, α = 0.0167 after
Bonferroni correction).
Correlation analysis, PCA and CA are different methods pro-
viding information on the interrelation of variables. While cor-
relation analysis describes the cross-covariance between two sets
of data, PCA identifies principal components accounting for the
variability of the data set. Cluster analysis in turn, groups a set of
variables in such a way that variables in the same group (cluster)
are more similar to each other than to those in other groups. In
order to gauge the extent of association between DAT binding
and motor/exploratory parameters, Spearman rank correlation
coefficients (r) were computed (α = 0.05) for V3” values and
behavioral data (traveled distance, duration and frequency of
ambulation, sitting, rearing, head-shoulder motility and groom-
ing in min 1–5, 6–10, 11–15, 16–20, 21–25, 26–30 and 1–30).
Calculations were performed using IBM SPSS Statistics 22. In
addition, data were subjected to a multivariate PCA and to a




Figure 1A shows characteristic images of [123I]FP-CIT accumula-
tions on coronal slices of rat brains after treatment with vehicle,
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FIGURE 2 | Traveled distance (cm) after vehicle (0.9% saline),
5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The figure shows box and
whisker plots of median distances traveled during the whole time of
testing (gray shade) and in the individual 5-min time bins.
25-/75-percentiles are given in the boxes, while 5-/95-percentiles are
represented by the whiskers. The circles represent the individual animals.
For significant between-group differences the respective p values are
given (two-tailed Mann–Whitney U test, α = 0.0167 after Bonferroni
correction). Inset: T-b curves obtained by plotting median values of
traveled distances against time and fitting exponential functions
(y(t) = a * exp (−K * x) + plateau with a, value at the time t; −K , rate
constant; t, time) to these data. For the comparisons between groups
(two-tailed F test, α = 0.0167 after Bonferroni correction) the respective
p values are given.
5 mg/kg L-DOPA or 10mg/kg L-DOPA. Striatal [123I]FP-CIT
accumulations were markedly reduced following challenge with
both 5 and 10 mg/kg L-DOPA.
After vehicle, 5 mg/kg L-DOPA and 10 mg/kg L-DOPA, cere-
bellar radioactivity concentrations (data not shown) amounted to
881 ± 134 counts/pixel (mean ± standard deviation), 898 ± 295
counts/pixel and 851 ± 311 counts/pixel, respectively. No sig-
nificant between-group differences were obtained (0.835 ≤
p ≤ 0.983).
After application of 5 and 10 mg/kg L-DOPA (Figure 1B),
neostriatal V3” were 0.91 ± 0.21 and 1.02 ± 0.25, respectively.
After vehicle, V3” amounted to 1.20 ± 0.14. Significant dif-
ferences were obtained between 5 mg/kg L-DOPA and vehicle
(p < 0.0001). For the comparison between 10 mg/kg L-DOPA
and vehicle a p of 0.036 was obtained, which failed to reach
significance after Bonferroni correction. There was no significant
difference between 5 and 10 mg/kg L-DOPA (p = 0.159).
BEHAVIORAL STUDIES
Median differences and t-b curves—traveled distance
After treatment with 10 mg/kg L-DOPA, the median traveled
distance (Figure 2) decreased significantly relative to vehicle in
min 16–20 (p = 0.004) and 21–25 (p = 0.007) as well as over the
whole trial (p = 0.002). Differences between 5 mg/kg L-DOPA
and vehicle in min 21–25 (p = 0.042) and between 10 mg/kg in
min 11–15 (p = 0.038) failed to reach significance after Bonferroni
correction. Significant between-group differences became evident
around min 11.
T-b curves significantly differed between 5 (exponential fit; a,
5269 ± 200.2 [mean ± standard error]; K, 0.09 ± 0.01; plateau,
−98.71 ± 143.8;) and 10 mg/kg L-DOPA (a, 4713 ± 405.4; K,
0.12 ± 0.02; plateau, 41.02 ± 142.4; p = 0.004). Comparison of
t-b curves after 10 mg/kg L-DOPA and vehicle (a, 6102± 3347; K,
0.22± 0.11; plateau, 981.1± 231.1) yielded a p of 0.043, and, thus,
failed to reach statistical significance after Bonferroni correction.
Rate constant and plateau were higher after 10 relative to 5 mg/kg
L-DOPA suggesting a faster rate of decrease to a higher final level.
However, rate constant and plateau were lower than in the vehicle
condition, which indicated a slower rate of decrease to a lower final
level.
Ambulation
There was no significant difference in duration of ambulation
between animals treated with 5 mg/kg L-DOPA and vehicle
(Figure 3A). After 10 mg/kg L-DOPA, rats moved significantly
less than after vehicle in min 16–20 (p = 0.006) as well as
throughout the whole trial (p = 0.005). The reduction in ambu-
lation in min 21–25 after 10 mg/kg L-DOPA relative to vehicle
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FIGURE 3 | Ambulation. (A) Duration (s) and (B) frequency (n) after vehicle
(0.9% saline), 5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The figure shows box
and whisker plots of median ambulation durations during the whole time of
testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles
are given in the boxes, while 5-/95-percentiles are represented by the
whiskers. The circles represent the individual animals. For significant
between-group differences the respective p values are given (two-tailed
Mann–Whitney U test, α = 0.0167 after Bonferroni correction). Insets: T-b
curves obtained by plotting median values of ambulation durations (A) and
ambulation frequencies (B) against time and fitting exponential functions
(y(t) = a * exp (−K * x) + plateau with a, value at the time t; −K , rate
constant; t, time) to these data. For the comparisons between treatment
groups (two-tailed F test, α = 0.0167 after Bonferroni correction) the
respective p values are given.
failed to reach statistical significance after Bonferroni correction
(p = 0.049). Significant between-group differences were evident
around min 16.
Comparison of t-b curves between 10 mg/kg L-DOPA
(exponential fit; a, 213.1 ± 34.26; K, 0.13 ± 0.04; plateau,
−0.46 ± 9.72) and vehicle (a, 171.9 ± 61.53; K, 0.13 ± 0.08;
plateau, 32.06 ± 17.36) yielded a p of 0.05, and, thus failed to
reach statistical significance after Bonferroni correction. This is
underlined by the equality of rate constants. Yet, after L-DOPA,
the curve plateau was lower compared to vehicle suggesting a
lower final level.
Rats treated with 5 mg/kg L-DOPA displayed a significantly
lower ambulation frequency (Figure 3B) compared to vehicle in
min 21–25 (p = 0.008) as well as throughout the whole trial
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(p = 0.015). After 10 mg/kg L-DOPA, animals moved significantly
less frequently compared to the vehicle condition in min 11–
15, 16–20 and 21–25 as well as during the whole testing time
(0.0001 > p ≤ 0.008). Differences between 10 mg/kg L-DOPA
and vehicle in min 6–11 (p = 0.049) failed to reach statistical sig-
nificance after Bonferroni correction. Significant between-group
differences emerged around min 6.
T-b curves significantly differed between 10 mg/kg L-DOPA
(exponential fit; a, 44.42 ± 5.52; K, 0.17 ± 0.03; plateau, 1.66 ±
0.78) and vehicle (a, 63.5± 18.19; K, 0.15± 0.06; plateau, 6.21±
3.22; p = 0.0005) as well as between 10 and 5 mg/kg L-DOPA (a,
55.14 ± 4.03; K, 0.13 ± 0.02; plateau, 1.64 ± 1.16; p = 0.0005).
The curve plateau after 10 mg/kg was lower compared to vehicle,
whereas the rate constant was higher. This suggests that after 10
mg/kg L-DOPA, ambulatory frequency decreased at a faster rate
to a lower final level relative to vehicle. In addition, after 10 mg/kg
L-DOPA both rate constant and plateau were higher compared to
5 mg/kg L-DOPA indicating a faster rate of increase to a (slightly)
higher final level.
Sitting
Animals treated with 5 mg/kg L-DOPA exhibited significantly
longer sitting behavior (Figure 4A) in min 21–25 (p = 0.005)
as well as throughout the whole trial (p = 0.004) compared
to rats treated with vehicle. Differences between 5 mg/kg and
vehicle in min 1–5 (p = 0.053) and min 16–20 (p = 0.019)
failed to reach significance after Bonferroni correction. After 10
mg/kg L-DOPA, rats sat quietly for a significantly longer time
than in the vehicle condition in min 6–10, 16–20 and 21–25
as well as throughout the whole trial (0.0001 ≤ p ≤ 0.012).
Significant between-group differences were obvious from min
6–10 but temporarily disappeared during the third time frame
(min 11–15).
T-b curves significantly differed between 5 mg/kg L-DOPA
(linear fit; slope, 8.20 ± 0.99; y-intercept, −10.67 ± 19.30)
and vehicle (slope, 4.80 ± 0.128; y-intercept, −7.33 ± 24.97;
p= 0.006) as well as between 10 mg/kg L-DOPA (slope, 6.55± 1.7;
y-intercept, 36.47 ± 33.67) and vehicle (p = 0.014). The slope
of both L-DOPA curves exceeded the slope of the vehicle curve
indicating a faster rate of increase of sitting duration to a higher
final level.
Differences in sitting frequency (Figure 4B) between 5 mg/kg
and vehicle in min 1–5 (p = 0.020), min 6–10 (p = 0.029) and
min 21–25 (p = 0.032) did not reach significance after Bon-
ferroni correction. There was no significant difference in sitting
frequency between animals treated with 10 mg/kg L-DOPA and
vehicle.
There was a significant difference between t-b curves after
5 mg/kg L-DOPA (quadratic fit; a, 8.0 ± 0.87; b, 0.19 ± 0.11; c,
−0.01 ± 0.003) and vehicle (a, −3.77 ± 0.233; b, 1.12 ± 0.31; c,
−0.02 ± 0.01; p = 0.003), whereas the t-b curve after 10 mg/kg
L-DOPA (a, 3.1 ± 0.2.58; b, 0.56 ± 0.31; c, −0.01 ± 0.01) was
neither different from vehicle (p = 0.193) nor from 5 mg/kg L-
DOPA (p = 0.209). After 5 mg/kg L-DOPA, the linear term was
lower and the quadratic term was higher compared to vehicle
suggesting a slower rate of increase of sitting frequency to a higher
final level.
Rearing
After 5 mg/kg L-DOPA, rats reared (Figure 5A) for a signif-
icantly shorter time compared to vehicle-treated animals over
the whole trial (p = 0.004). Differences relative to vehicle in
min 11–15 (p = 0.022), min 21–25 (p = 0.020) and min 26–30
(p = 0.038) did not reach significance after Bonferroni correction.
Rearing was also significantly shorter after 10 mg/kg L-DOPA
compared to vehicle-treated rats in min 21–25 (p = 0.009) as
well as over the whole trial (p = 0.001). Differences relative to
vehicle in min 11–15 (p = 0.031) and min 16–20 (p = 0.022)
and min 21–25 failed to reach significance after Bonferroni cor-
rection. Significant between-group differences emerged around
min 21.
The difference between t-b curves after 10 mg/kg L-DOPA
(exponential fit; a, 100.9 ± 11.27; K, 0.13 ± 0.02; plateau,
−4.1 ± 3.17) and vehicle (a, 91.47 ± 40.44; K, 0.05 ± 0.07;
plateau, −9.90 ± 57.18) with a p of 0.024 did not reach
significance after Bonferroni correction. This also held for
the difference between t-b curves after 5 mg/kg L-DOPA (a,
153.1 ± 42.17; K, 0.19 ± 0.06; plateau, 2.2 ± 3.9 and vehicle
(p = 0.061). Yet, the rate constants of both L-DOPA curves
exceeded those of the vehicle curve indicating a faster rate of
decrease of rearing, while the higher plateau values implied a
higher final level of rearing duration after L-DOPA relative to
vehicle.
After 5 mg/kg L-DOPA, rats reared significantly less fre-
quently (Figure 5B) compared to the vehicle condition in min
11–15 (p = 0.013) as well as throughout the whole testing
time (p = 0.013). Differences relative to vehicle in min 21–25
(p = 0.035) and min 26–30 (p = 0.032) failed to reach statistical
significance after Bonferroni correction. After 10 mg/kg L-DOPA,
rearing frequency was significantly lower than in vehicle-treated
rats in min 11–15 (p = 0.003) and min 21–25 (p = 0.008) as
well as over the whole trial (p = 0.002), whereas differences in
min 6–10 (p = 0.034), min 16–20 (p = 0.022) and min 21–25
(p = 0.035) failed to reach significance after Bonferroni cor-
rection. Significant between-group differences emerged around
min 11.
Comparison of t-b curves after 10 mg/kg L-DOPA (exponen-
tial fit; a, 47.05 ± 11.79; K, 0.21 ± 0.05; plateau, −0.047 ± 0.95)
and vehicle (a, 32.39± 6.21; K, 0.12± 0.04; plateau, 1.64± 2.40)
yielded a p of 0.024, and, thus, after Bonferroni correction did
not reach significance. Yet, the higher rate constant after 10 mg/kg
L-DOPA suggested a faster rate of decrease of rearing frequency,
while the lower plateau value indicated a lower final level of
rearing frequency compared to vehicle.
Head-shoulder motility
After treatment with 5 mg/kg L-DOPA, the duration of
head-shoulder motility (Figure 6A) was significantly reduced
relative to vehicle in min 6–10 (p = 0.017) and min 21–25
(p = 0.010) as well as over the whole trial (p = 0.001). Dif-
ferences relative to vehicle in min 11–15 (p = 0.035), min
16–20 (p = 0.038) and min 26–30 (p = 0.045) failed to reach
significance after Bonferroni correction. Head-shoulder motil-
ity was also significantly shorter after with 10 mg/kg L-DOPA
relative to vehicle in min 6–10, 11–15, 16–20 and 21–25 as
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FIGURE 4 | Sitting. (A) Duration (s) and (B) frequency (n) after vehicle
(0.9% saline), 5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The figure
shows box and whisker plots of median sitting durations during the
whole time of testing (gray shade) and in the individual 5-min time
bins. 25-/75-percentiles are given in the boxes, while 25-/95-percentiles
are represented by the whiskers. The circles represent the individual
animals. For significant between-group differences the respective p
values are given (two-tailed Mann–Whitney U test, α = 0.0167 after
Bonferroni correction). Insets: T-b curves obtained by plotting median
values of sitting durations (A) and sitting frequencies (B) against time.
Linear functions (y = ax + b with a, slope and b, y -intercept) were
fitted to the plots of sitting durations, whereas quadrtatic functions
(y = a + bx + cx2 with a, absolute term; bx, linear term; cx2,
quadratic term) were fitted to the plots of sitting frequencies. For the
comparisons between treatment groups (two-tailed F test, α = 0.0167
after Bonferroni correction) the respective p values are given.
well as from min 1–30 (0.0001 ≤ p ≤ 0.012). The differences
relative to vehicle in min 1–5 with a p of 0.018 marginally
failed to reach statistical significance after Bonferroni correc-
tion. Significant between-group differences were obtained from
min 6.
T-b curves differed significantly between 5 mg/kg L-DOPA
(quadratic fit; a, 40.3 ± 10.61; b, 3.42 ± 1.39; c; −0.13 ± 0.04)
and vehicle (a: 34.0 ± 7.41; b, 8.43 ± 0.97; c; −0.25 ± 0.03;
p = 0.0002) as well as between 10 mg/kg L-DOPA (a, 43.2 ±
11.18; b, 1.30 ± 1.46; c; −0.05 ± 0.04) and vehicle (p < 0.0001).
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FIGURE 5 | Rearing. (A) duration (s) and (B) frequency (n) after vehicle
(0.9% saline), 5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The figure shows
box and whisker plots of median rearing durations during the whole time of
testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles
are given in the boxes, while 25-/95-percentiles are represented by the
whiskers. The circles represent the individual animals. For significant
between-group differences the respective p values are given (two-tailed
Mann–Whitney U test, α = 0.0167 after Bonferroni correction). Inset: T-b
curves obtained by plotting median values of rearing durations (A) and
rearing frequencies (B) against time and fitting exponential functions
(y(t) = a * exp (−K * x) + plateau with a, value at the time t; −K , rate
constant; t, time) to these data. For the comparisons between treatment
groups (two-tailed F test, α = 0.0167 after Bonferroni correction) the
respective p values are given.
After both L-DOPA doses, linear and quadratic terms fell short of
linear and quadratic terms after vehicle suggesting a slower rate of
increase of head-shoulder motility to a lower final level compared
to vehicle.
Rats treated with 5 mg/kg L-DOPA moved their head and
shoulders (Figure 6B) significantly less frequently throughout the
whole testing time (p = 0.005). Differences relative to vehicle in
min 11–15 (p = 0.035), min 16–20 (p = 0.029) and min 26–30
(p= 0.029) failed to reach significance after Bonferroni correction.
Head and shoulders were also moved significantly less frequently
in rats treated with 10 mg/kg L-DOPA compared to vehicle in min
1–5, 6–10, 11–15, 16–20 and 21–25 as well as over the whole trial
(0.0001≤ p≤ 0.005). Significant between-group differences were
evident from the beginning.
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FIGURE 6 | Head-shoulder motility. (A) Duration (s) and (B) frequency (n)
after vehicle (0.9% saline), 5 mg/kg L-DOPA and 10 mg/kg L-DOPA. The
figure shows box and whisker plots of median durations of head-shoulder
motility during the whole time of testing (gray shade) and in the individual
5-min time bins. 25-/75-percentiles are given in the boxes, while
25-/95-percentiles are represented by the whiskers. The circles represent
the individual animals. For significant between-group differences the
respective p values are given (two-tailed Mann–Whitney U test, α = 0.0167
after Bonferroni correction). Insets: T-b curves obtained by plotting median
values of motility durations (A) and frequencies (B) against time. Quadratic
functions (y = a + bx + cx2 with a, absolute term; bx, linear term; cx2,
quadratic term) were fitted to the plots of motility durations, while linear
functions (y = ax + b with a, slope and b, y -intercept) were fitted to the
plots of motility frequencies. For the comparisons between groups
(two-tailed F test, α = 0.0167 after Bonferroni correction) the respective p
values are given.
T-b curves differed significantly between 5 mg/kg L-DOPA
(linear fit; slope, −0.37 ± 0.12; y-intercept, 20.33 ± 2.40) and
vehicle (slope,−0.45± 0.06; y-intercept, 26.80± 1.24; p = 0.007)
as well as between 10 mg/kg L-DOPA (slope, −0.28 ± 06; y-
intercept, 17.07 ± 1.19; vehicle: slope, −0.45 ± 0.06; y-intercept,
28.80 ± 1.24; p < 0.0001) and vehicle. The absolute values
of the slopes after both L-DOPA doses were lower than slope
after vehicle indicating that the frequency of head and shoulder
motility decreased at a slower rate to a lower final level relative to
vehicle.
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Table 1 | Main results of principal component analysis.
PCs % of VAR accounted Eigenvectors with the highest % of VAR accounted for by the eigenvectors
for by PCs contribution to PCs with the highest contribution to PCs
PC1 78.9 traveled distance in min 1–30 10.6
PC2 8.3 traveled distance in min 26–30 48.3
PC3 5.9 traveled distance in min 26–30 50.0
PC4 2.7 traveled distance in min 6–10 70.4
PC5 2.2 traveled distance in min 26–30 54.6
PC6 1.1 traveled distance in min 11–15 17.6
PC7 0.04 traveled distance in min 1–30 10.6
PC, principal component; VAR, variance.
Grooming
After 10 mg/kg L-DOPA, rats groomed for a significantly shorter
time compared to animals treated with vehicle (p = 0.041; data
not shown). There were no other significant between-group dif-
ferences of grooming behavior.
CORRELATION OF MOTOR/EXPLORATORY BEHAVIORS WITH DAT
BINDING
After vehicle, DAT binding correlated positively with rearing
frequency in min 21–25 (r = 0.546, p = 0.028) and duration
of head-shoulder motility in min 21–25 (r = 0.586, p = 0.017).
A marginal correlation was obtained between DAT binding and
rearing duration in min 26–30 (r = 0.481, p = 0.058).
After 5 mg/kg L-DOPA, DAT binding correlated negatively
with sitting frequency in min 11–15 (r = 0.635, p = 0.010) and
positively with both duration (r = 0.523, p = 0.045) and frequency
of head-shoulder motility in min 16–20 (r = 0.620, p = 0.013).
No significant correlations with behavioral parameters were
observed after 10 mg/kg L-DOPA (0.072 ≤ p ≤ 0.892).
PCA AND CA
The PCA revealed that 79% of the cumulative variance could be
explained by the first principal componenet (PC1), while PC2
to PC7 added up to 87%, 93%, 98% and 100%, respectively, of
the cumulative variance (Table 1). The major eigenvector com-
ponent of PC1 was “traveled distance” in min 1–30. The major
eigenvector components of PC2 to PC7 were “traveled distance”
in min 21–25, 6–10, 11–15 and 1–30, respectively (Table 1).
The contribution of V3” to the individual principal components
amounted to 0.
The CA evidenced that the data set could be grouped into
four clusters comprising 19, 12, 14 and 7 rats. Table 2 lists the
centroid means of all variables in cluster 1–4. Thereby, cluster 1
displayed the lowest V3”, and the shortest traveled distance, the
shortest ambulation duration, the lowest ambulation frequency,
the longest sitting duration, the highest sitting frequency, the
shortest rearing duration, the lowest rearing frequency, the short-
est duration of head-shoulder motility and the lowest frequency of
head-shoulder motility in the individual time frames. In contrast,
cluster 4 was characterized by the highest V3”, and the longest
traveled distance, the longest ambulation duration, the highest
ambulation frequency, the shortest sitting duration, the lowest
sitting frequency, the highest rearing duration, the highest rearing
frequency, the longest duration of head-shoulder motility and
the highest frequency of head-shoulder motility in the individual
time frames. In cluster 2 and 3 intermediate centroid means were
obtained for each of these variables.
DISCUSSION
DAT BINDING
Challenge with 5 mg/kg L-DOPA/benserazide reduced DAT bind-
ing significantly by 23% relative to vehicle. The 14% reduction
obtained after 10 mg/kg L-DOPA was not significant after Bon-
ferroni correction. Cerebellar radioactivity concentrations did not
differ between vehicle and L-DOPA challenges, indicating that no
confounding effects were exerted on radioligand accumulation,
e.g., by affecting cerebral perfusion.
Findings are consistent with previous findings obtained in
PD patients (Guttman et al., 2001) and rats (Dresel et al., 1998;
Sossi et al., 2010; Nikolaus et al., 2011b, 2013). They contradict,
however, other findings in parkinsonian humans (Nurmi et al.,
2000; Parkinson Study Group, 2002, 2004; Schillaci et al., 2005)
and non-human primates (Laruelle et al., 1993; Fernagut et al.,
2010). Sossi et al. (2010) were the first to demonstrate differential
effects of L-DOPA on radioligand binding to the DAT dependent
on the intactness or degeneration of the neostriatum in a rat
model of PD. Their findings suggest that the extent of nigros-
triatal neurodegeneration determines the number of available
DAT binding sites, the capacity to synthesize and release DA
contingent on administration of the precursor molecule and,
consequently, also the extent, to which the exogeous radioligand
may bind to the DAT. Accordingly, PD patients, who displayed
a significant decrease of DAT binding after long-term treatment
with L-DOPA had a mean Unified Parkinson’s Disease Rating
Scale (UPDRS) score of 23.9 ± 6.0 (Guttman et al., 2001),
whereas in studies, in which no alterations of DAT binding were
observed, mean UPDRS scores were 17–47% higher (Schillaci
et al., 2005: UPDRS, 35.1 ± 11.8; Nurmi et al., 2000: UPDRS,
31.0 ± 48.0; Parkinson Study Group, 2002: UPDRS, 30.6 ±
11.4; Parkinson Study Group, 2004: UPDRS, 28.0 ± 13.0). Also
findings of reduced radioligand binding to the DAT as obtained in
healthy rats in the present and in previous investigations (Dresel
et al., 1998; Nikolaus et al., 2011b, 2013) are consistent with this
assumption.
Since L-DOPA increases DA efflux (for review see Misu et al.,
1996), the reduction of DAT binding may be interpreted in terms
of competition between [123I]FP-CIT and endogenous DA. A
further mechanism likely to occur at the presynaptic terminal
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Table 2 | Centroid means of the individual variables obtained from cluster analysis.
Variable Cluster 1 Cluster 2 Cluster 3 Cluster 4
V3” 0.98 1.05 1.09 1.2
traveled distance in min 1–30 (cm) 4931 7474 9246 1234
traveled distance in min 1–5 (cm) 1960 2964 3481 3963
traveled distance in min 5–10 (cm) 782 1907 2125 2643
traveled distance in min 11–15 (cm) 865 1162 1335 1835
traveled distance in min 16–20 (cm) 396 567 7305 1546
traveled distance in min 21–55 (cm) 516 673 984 1528
traveled distance in min 26–30 (cm) 409 200 592 827
ambulation duration in min 1–30 (s) 228 284 396 453
ambulation duration in min 1–5 (s) 90 117 133 135
ambulation duration in min 6–10 (s) 46 67 95 98
ambulation duration in min 11–15 (s) 35 42 52 68
ambulation duration in min 16–20 (s) 14 23 30 63
ambulation duration in min 21–25 (s) 24 30 43 56
ambulation duration in min 26–30 (s) 3 2 6 8
ambulation frequency in min 1–30 (n) 43 67 90 123
ambulation frequency in min 1–5 (n) 18 30 34 41
ambulation frequency in min 6–10 (n) 7 17 21 26
ambulation frequency in min 11–15 (n) 7 10 13 18
ambulation frequency in min 16–20 (n) 3 4 7 15
ambulation frequency in min 21–25 (n) 5 5 8 15
ambulation frequency in min 26–30 (n) 18 10 33 32
sitting duration in min 1–30 (s) 1043 857 588 354
sitting duration in min 1–5 (s) 113 45 28 20
sitting duration in min 6–10 (s) 150 63 38 33
sitting duration in min 11–15 (s) 175 116 71 61
sitting duration in min 16–20 (s) 215 173 148 74
sitting duration in min 21–25 (s) 186 184 126 90
sitting duration in min 26–30 (s) 219 253 193 77
sitting frequency in min 1–30 (n) 56 45 44 35
sitting frequency in min 1–5 (n) 9 6 5 4
sitting frequency in min 6–10 (n) 9 8 6 5
sitting frequency in min 11–15 (n) 11 9 8 6
sitting frequency in min 16–20 (n) 10 10 10 7
sitting frequency in min 21–25 (n) 8 8 8 6
sitting frequency in min 26–30 (n) 7 8 9 6
rearing duration in min 1–30 (s) 79 130 201 284
rearing duration in min 1–5 (s) 32 57 70 86
rearing duration in min 6–10 (s) 16 38 50 67
rearing duration in min 11–15 (s) 11 19 33 44
rearing duration in min 16–20 (s) 6 10 11 38
rearing duration in min 21–25 (s) 11 7 25 34
rearing duration in min 26–30 (s 5 0 12 14
rearing frequency in min 1–30 (n) 22 40 54 84
rearing frequency in min 1–5 (n) 11 20 24 31
rearing frequency in min 6–10 (n) 4 11 13 20
rearing frequency in min 11–15 (n) 3 5 7, 5 12
rearing frequency in min 16–20 (n) 1 2 3 7
rearing frequency in min 21–25 (n) 2 2 5 10
rearing frequency in min 26–30 (n) 1 0 2 3
head-shoulder motility duration in min 1–30 (s) 354 363 410 499
head-shoulder motility duration in min 1–5 (s) 57 62 63 57
head-shoulder motility duration in min 6–10 (s) 65 89 90 83
head-shoulder motility duration in min 11–15 (s) 65 78 79 86
head-shoulder motility duration in min 16–20 (s) 56 59 75 103
head-shoulder motility duration in min 21–25 (s) 56 48 59 94
head-shoulder motility duration in min 26–30 (s) 43 33 50 74
head-shoulder motility frequency in min 1–30 (n) 79 84 98 123
head-shoulder motility frequency in min 1–5 (n) 14 195 22 25
(Continued)
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Table 2 | Continued
Variable Cluster 1 Cluster 2 Cluster 3 Cluster 4
head-shoulder motility frequency in min 6–10 (n) 13 19 21 26
head-shoulder motility frequency in min 11–15 (n) 15 17 18 20
head-shoulder motility frequency in min 16–20 (n) 12 13 15 21
head-shoulder motility frequency in min 21–25 (n) 11 11 13 19
head-shoulder motility frequency in min 26–30 (n) 9 8 11 14
in response to increased DA levels is the up-regulation of DAT
binding sites (for review see Eriksen et al., 2010). As, however,
DAT binding was found to be decreased after L-DOPA challenge,
it can be concluded that at the time of [123I]FP-CIT administra-
tion DA levels had risen to an extent surmounting the capacity
of DA reuptake by the available DAT binding sites. Thereby, it
remains to be seen, whether and under which conditions the
number of DAT binding sites in relation to synaptic DA con-
centrations can rise by such a degree that direct competition
between [123I]FP-CIT and DA is avoided by DA reuptake in a
sufficient quantity. If this can be the case, it was not detected
with the L-DOPA doses and the time window between L-DOPA
challenge and [123I]FP-CIT administration chosen in the present
investigation.
Anesthetics inevitably influence the brain’s neurotransmitter
systems. We employed ketamine, a compound, which has been
found to increase the levels of DA, noradrenaline and other
neurotransmitters in cortical and subcortical regions (for review
see De Souza Silva et al., 2007; Müller et al., 2011). Since in
our study L-DOPA- as well as saline-treated rats had undergone
anesthesia prior to radioligand injection, it cannot be dismissed
that DA levels were elevated by ketamine in both experimental
conditions. In this case it may be expected, however, that the
comparability of experimental conditions was preserved by the
application of ketamine to both treatment groups. Ketamine
may also have exerted different effects in L-DOPA and saline-
treated rats, in which case, ketamine may have at least contributed
to the L-DOPA-induced increase of striatal DA levels. Further
investigations are needed, which explicitly address this question.
RAT BEHAVIOR—MEDIAN DIFFERENCES AND T-B CURVES
After both L-DOPA doses, the median sitting duration was higher
compared to vehicle, while median duration and frequency of
head-shoulder motility were lower. Findings are consistent with
previous reports of reduced behavioral activity after administra-
tion of the DA precursor molecule in moderate doses (McDevitt
and Setler, 1981).
As evidenced by Figures 2–6, the reductions of motor/exp-
loratory behaviors and the increase of sitting after both L-DOPA
doses relative to vehicle became significant around the sec-
ond to third time frame (min 6–15). This coincides with the
onset of measurable DA release, which in in vivo microdialysis
studies was observed between min 5 and 15 after i.p. injec-
tion of L-DOPA (e.g., De Souza Silva et al., 1997a,b; Meissner
et al., 2006) suggesting an association between the reduction
of behavioral activity and the increased availability of endoge-
nous DA in min 5–15 post-injection. Fifteen minutes after i.p.
application of 25 (Meissner et al., 2006) and 50 mg/kg L-DOPA
plus benserazide (De Souza Silva et al., 1997b), neostriatal DA
concentrations reached 170% and 900%, respectively, of base-
line levels. From this it may be concluded that also the lower
L-DOPA doses employed in the present investigation elevated
neostriatal DA to levels sufficient to decrease motor/exploratory
behaviors and to compete with [123I]FP-CIT for DAT binding
sites.
In the present study, the analysis of t-b curves for measures
of sitting and head-shoulder motility yielded higher slopes and
smaller constants in the linear and quadratic terms after both
L-DOPA doses relative to vehicle indicating (1) a faster rate
of increase of sitting duration to a higher final level; (2) a
slower rate of increase of head-shoulder motility duration to
a lower final level; and (3) a slower rate of decrease of head-
shoulder motility frequency to a lower final level. In addi-
tion, the analysis of rearing duration curves yielded evidence
of higher rate constants and lower plateau values after L-DOPA
compared to vehicle suggesting a faster rate of decrease in
rearing to a lower final level after L-DOPA relative to vehi-
cle. These findings evidence a time-dependent decline of motor
and exploratory behaviors in the open field. The waning of
exploratory activities such as rearing and head-shoulder motility
as well as the increase of sitting behavior within or between
trials is generally considered to reflect behavioral habituation
(for review see Leussis and Bolivar, 2006). Since these behav-
ioral alterations are likely to be related to the L-DOPA-induced
increase of endogenous DA levels in the neostriatum and DA
is known to be involved in learning and memory (for review
see Myhrer, 2003), the decline of behavioral markers of activ-
ity after L-DOPA also in the present investigation may be due
to its action on the rate of behavioral habituation to a novel
environment.
Behavioral alterations relative to vehicle were more pro-
nounced after the higher dose of L-DOPA and related to more
behavioral measures, which may be due to a larger effect on
endogenous DA levels. This is not consistent with effects on
DAT binding, as results indicated a biphasic response with a
higher effect on DAT after the lower dose of L-DOPA. Biphasic
regulatory actions of L-DOPA on DA and other neurotransmitters
including noradrenaline and acetylcholine are widely known (for
review see Misu et al., 1996) and raise the question, by which
mechanisms the disparate effects on DA efflux and DAT binding
are exerted. Dopamine release is modulated by a negative feed-
back loop established by DA acting upon presynaptic terminal
autoreceptors of the inhibitory D2/3 receptor subtype (for review
see Langer, 1997). Therefore, it may be that DA concentrations
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after 10 mg/kg L-DOPA at the time of radioligand application
were lower compared to the 5 mg/kg dose, because in the 30 min
time span between its application and the administration of the
radioligand the higher dose may have promoted the release of
DA in concentrations sufficient to activate feedback inhibition
at the presynaptic terminal. If this was the case, neostriatal V3”
values after higher L-DOPA doses can not be assumed to reflect
DA levels at the time of data acquisition in the open field. This
agrees with the in vitro finding of inhibited DA release after
micromolar relative to nanomolar concentrations of L-DOPA (for
review see Misu et al., 1996), and is also consistent with the
slightly higher mean V3” values observed after 10 relative to 5
mg/kg L-DOPA in the present study (Figure 1). Further studies
with higher doses of L-DOPA are required to shed further light
on this matter.
CORRELATION ANALYSIS, PCA AND CA
After vehicle, DAT binding correlated positively with rearing
duration (min 26–30) and frequency (min 21–25) as well as
duration of head-shoulder motility (min 21–25). After 5 mg/kg L-
DOPA, DAT binding correlated negatively with sitting frequency
(min 11–15), and positively with both duration and frequency
of head-shoulder motility (min 16–20). Correlation coefficients
were low but significantly different from 0. No correlations with
behavioral parameters were observed after 10 mg/kg L-DOPA.
The moderate association between DAT binding and param-
eters of motor and exploratory behavior was in agreement with
the results of PCA and CA. The PCA revealed that the major
part of the variance in the data set could be explained by the
variable “traveled distance” in min 1–30. Cluster analysis, in
addition, evidenced that the centroid means of V3” (0.98, 1.05,
1.09 and 1.2) were contiguous, but still could be related to
varying means of motor and exploratory parameters. Thereby,
in accordance with the results of correlation analysis, lower DAT
binding was associated with a decrease of exploratory behav-
iors (rearing and head-shoulder motility) and an increase of
sitting, whereas higher DAT binding was observed jointly with
increased exploratory behaviors and decreased sitting. In addi-
tion to the findings obtained from correlation analysis, DAT
binding could also be related to ambulation with lower DAT
binding associated with a lower and higher DAT binding asso-
ciated with a higher ambulatory activity. As the reduction of
striatal DAT binding contingent on the administration of L-
DOPA reflects the increased availability of DA, it follows that a
higher amount of neostriatal DA decreased motor/exploratory
behaviors and facilitated sitting. According to the results of cor-
relation analysis, this relation holds for both vehicle and 5 mg/kg
L-DOPA, which underlines the general importance of DA for
either behavior.
It is, however, important to note that according to the PCA,
the most relevant eigenvector component is the traveled dis-
tance but not the neostriatal V3”. This suggests a merely mod-
erate association between motor/exploratory and neostriatal DA
function, which is in agreement with previous evidence on the
relevance of brain regions beyond the neostriatum (such as the
hippocampus and the prefrontal cortex) for the unfolding of
central L-DOPA action (Navailles et al., 2010). It is also consistent
with the role assigned to neurotransmitters beyond DA (such
as serotonin, acetylcholine and glutamate) for motor activity as
well as habituation learning (e.g., Dringenberg et al., 1995; Carey
et al., 1998; Schildein et al., 2002). In order to gain further infor-
mation on this matter, future investigations are needed, which
jointly assess the effect of serotonin, acetylcholine and glutamate
action on DAT binding and parameters of motor and exploratory
behaviors.
The modest role of the neostriatal V3” in explaining the
variance of behavioral data may be also due to the time span
between the acquisition of behavioral data (immediately after the
administration of L-DOPA or vehicle) and DAT imaging (150 min
post-challenge). It can not be dismissed that V3” values (and DA
levels) at the time of in vivo imaging no longer corresponded
to the DA levels at the time of data acquisition in the open
field. Future investigations, in which behavior after L-DOPA is
measured for a longer time than 30 min. Besides, DAT binding
should be asseessed in different sets of animals at various time
after the injection of the radioligand.
CONCLUSIONS
The present complementary investigation of DAT binding and
behavioral parameters yielded mean reductions of striatal DAT
binding after L-DOPA, which reflected increased availability of
endogenous DA. As L-DOPA-treated animals displayed less head-
shoulder motility and more sitting than vehicle-treated animals,
we hypothesize that the decrease of behavioral activity is asso-
ciated with the increased availibility of DA. The analysis of t-b
curves for sitting duration and duration as well as frequency of
head-shoulder motility yielded higher slopes as well as smaller
constants in the linear and quadratic terms after both L-DOPA
doses relative to vehicle, which indicate (1) a faster rate of increase
of sitting duration to a higher final level; (2) a slower rate of
increase of head-shoulder motility duration to a lower final level;
and (3) a slower rate of decrease of head-shoulder motility fre-
quency to a lower final level. In addition, the analysis of rearing
duration curves yielded higher rate constants and lower plateau
values after L-DOPA compared to vehicle indicating a faster rate
of decrease of rearing duration a lower final level of rearing
duration after L-DOPA relative to vehicle. These findings suggest
that decline of behavioral markers of activity after L-DOPA may
be due to its action on the rate of behavioral habituation to a novel
environment.
We here present a novel approach, which assesses between-
group differences of behavioral alterations by fitting suitable
models to the acquired data and statistically comparing t-b curves.
The benefit of this method is the gaining of information on
the temporal dynamics of behavior, which is not the case with
the standard approach of creating dose-response curves relating
alterations of behavior to dose but not to time. Importantly, the
differences obtained between t-b curves are confirmed by the
median differences between the individual time frames, which, on
the one hand, served as an internal validation of the t-b approach.
On the other hand, however, the calculation of median values in
the individual time frames contributed information on the onset
of behavioral alterations (and habituation learning), which may
be fixed to min 6–15 after i.p. application of L-DOPA. Alterations
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of behavioral settings and procedures (e.g., application of higher
or lower L-DOPA doses or a longer acquisition time of behav-
ioral data) may be expected to lead to a further refinement
of the individual t-b models. In addition, future investigations
will reveal, to which extent the present approach of fitting and
comparing t-b curves between treatments may be transferred to
pharmacological challenges with other compounds affecting the
DAergic system.
Since (motor) behavior in adult rats is also associated with
D1 (for review see Undieh, 2010) and D2 receptor function (for
review see Helmeste, 1983), the present investigations should
be complemented by adding in vivo imaging of D1 and/or D2
receptor binding to the assessment of behavioral data. As the
binding of exogenous radioligands may depend on the intact-
ness of the neostriatum, joint investigation of DAT and/or D2
receptor binding and behaviors in 6-hydroxydopamine-lesioned
animals should be added in order to gauge the effects of L-DOPA
in relation to unlesioned rats. Common features of long-term
treatment of with L-DOPA, in parkinsonian humans are move-
ment disturbances including dyskinesias, on-off-phenomenon
and wearing-off phenomenon (for review see Cenci et al., 2011).
Therefore, further in vivo imaging studies on rats over a wider
clinical dose range and, in particular, after long-term treat-
ment with L-DOPA will help to unravel not only the regulatory
mechanisms underlying DA synthesis and release but also the
association of DAT and D1/D2 receptor binding with behavioral
features.
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